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Abstract
Background: Estimating input costs for Markov models in health economic evaluations requires health state–specific
costing. This is a challenge in mental illnesses such as depression, as interventions are not clearly related to health
states. We present a hybrid approach to health state–specific cost estimation for a German health economic evalua-
tion of antidepressants. Methods: Costs were determined from the perspective of the community of persons insured
by statutory health insurance (‘‘SHI insuree perspective’’) and included costs for outpatient care, inpatient care,
drugs, and psychotherapy. In an additional step, costs for rehabilitation and productivity losses were calculated from
the societal perspective. We collected resource use data in a stepwise hierarchical approach using SHI claims data,
where available, followed by data from clinical guidelines and expert surveys. Bottom-up and top-down costing
approaches were combined. Results: Depending on the drug strategy and health state, the average input costs varied
per patient per 8-week Markov cycle. The highest costs occurred for agomelatine in the health state first-line treat-
ment (FT) (‘‘FT relapse’’) with e506 from the SHI insuree perspective and e724 from the societal perspective. From
both perspectives, the lowest costs (excluding placebo) were e55 for selective serotonin reuptake inhibitors in the
health state ‘‘FT remission.’’ Conclusion: To estimate costs in health economic evaluations of treatments for depres-
sion, it can be necessary to link different data sources and costing approaches systematically to meet the require-
ments of the decision-analytic model. As this can increase complexity, the corresponding calculations should be
presented transparently. The approach presented could provide useful input for future models.
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The estimation of input costs in Markov models remains
a challenge. This is due to the fact that costs are primar-
ily attributable to health care interventions and not to
health states, as required in Markov models.1,2 Relating
costs to health states is particularly problematic for men-
tal illnesses, as specific interventions are not clearly asso-
ciated to specific health states. For instance, the costs
incurred by moderately to severely depressed patients
after response to treatment or after remission are virtu-
ally nonidentifiable in statutory health insurance (SHI)
claims data, since these health states are not coded
accordingly.
In the majority of health economic evaluations of
antidepressants, resource use in the different health states
is therefore estimated on the basis of expert opinion3 or
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in some cases derived directly from clinical studies.4–6
However, the limitations of these methods have been
extensively discussed.7–9 For instance, data obtained from
the aforementioned sources might be highly context-
dependent and not readily transferable to the real-life
treatment setting. Moreover, even if health state–specific
costs are specified, authors of health economic studies on
depression often do not describe how costs were attributed
to the different health states and/or provide information
on the calculation approach applied.4–6,10–13
This article presents a hybrid approach to health
state–specific cost estimation. Our aim was to combine
information from the (rather normative) evidence-based
guideline recommendations and the (experience-based)
expert surveys in order to complement patient-specific
SHI claims data, thus enabling the transparent allocation
of costs to different health states. We chose this approach
to reflect the true costs incurred over a specified time
period as accurately as possible.
The illustrated costing approach was applied within a
health economic evaluation of antidepressants by the
German Institute for Quality and Efficiency in Health
Care (IQWiG) using the efficiency frontier approach.
The evaluation was conducted to derive recommenda-
tions on reimbursement prices for newer antidepressants.
It used effectiveness data from two previously conducted
IQWiG benefit assessments.14,15 Costs and effectiveness
were combined in a Markov cohort simulation model
with eight health states. Two time horizons were consid-
ered: first a short-term time horizon of 2 months and
additionally a 1-year time horizon. The model included
four newer antidepressants (venlafaxine, duloxetine,
bupropion, and mirtazapine) whose cost-effectiveness
was compared to a range of comparator drugs: tricyclic
antidepressants (TCAs) including the tetracyclic mapro-
tiline, selective serotonin reuptake inhibitors (SSRIs),
agomelatine, and trazodone. If drug classes were investi-
gated, only one main agent per drug class was consid-
ered, as specified in the prior benefit assessments.14,15
Publishing the estimation of input costs of a health
economic model in a stand-alone paper and not together
with modelling results allows the presentation in more
detail of the methods applied and the corresponding
results. The objective of this article is to transparently
describe our approach for generating input costs for the
health states of a Markov model comparing antidepres-
sant treatment alternatives. This includes the presenta-
tion of individual calculations, which might provide
useful support or even input for future models. The gen-
eration of effect estimates, the development of the
decision-analytic model, the results of the health eco-
nomic evaluation using the efficiency frontier approach,
and the management of uncertainty have been described
in the respective IQWiG report.16
Methods
Framework
All costs were determined from the perspective of the
community of persons insured by the SHI funds (SHI
insuree perspective for short), as stipulated by German
law. This perspective includes all costs reimbursed by the
SHI, as well as co-payments.17 Costs were estimated for
the following four main cost categories: outpatient care
(general practitioners [GPs], specialists, and laboratory
tests), drugs, psychotherapy, and inpatient care. As an
additional perspective, we also included two cost compo-
nents of the societal perspective, namely, costs incurred
by rehabilitation and productivity losses.
Costs were derived for the input parameters of a
decision-analytic Markov model. The model simulated
the disease and its treatment, taking into account the dif-
ferent health states representing the specific disease
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stages and possible treatment outcomes. Figure 1 shows
a simplified outline of the health states and possible tran-
sitions between health states.
The following health states were considered for first-
line treatment (FT) of depression:
 Acute treatment = ‘‘FT acute’’
 Continued treatment after achievement of response
= ‘‘FT response’’
 Continued treatment after achievement of remission
= ‘‘FT remission’’
 Continued treatment after relapse = ‘‘FT relapse’’
The following health states were considered for second-
line treatment (ST) of depression:
 Continued treatment after treatment discontinuation
due to adverse events = ‘‘ST after disc. due to AEs’’
 Continued treatment after no response = ‘‘ST no
response’’
 Continued treatment after response/remission achieved
in ST after discontinuation of FT = ‘‘ST response/
remission after FT disc’’
 Continued treatment after relapse = ‘‘ST relapse’’
Costs were calculated per 8-week period, the cycle length
in the Markov model. We computed all costs in a two-
step process. First, we identified the resource use and
related costs for each cost category. Second, we trans-
ferred the information for each cost category to the sin-
gle health states (‘‘health state costing’’). We preferably
measured resource quantities on basis of individual
patients (bottom-up approach) but used average values
(top-down approach) if individual data were not avail-
able. We estimated the costs for the resource use either
with the micro-costing approach (identifying every single
cost component) or the macro-costing approach (identi-
fying costs at an aggregated level), depending on which
approach was reasonable in the respective context.18
Data Sources
Costs were extracted from SHI claims data where avail-
able. Claims data provided by the second largest German
SHI fund, the Barmer GEK, were analyzed for the year
2010. The data set included data on 3,888,548 Barmer
GEK members from all regions in Germany. The data
used for costing were matched to the clinical study popu-
lations of the IQWiG benefit assessments.14,15 The fol-
lowing inclusion criteria applied: 1) age between 18 and
65 years; 2) continuously insured in 2010; 3) current treat-
ment with one of the study or comparator drugs investi-
gated, but no treatment with any antidepressant for at
least 6 months prior to the start of treatment with the
study or comparator drug; 4) diagnosis of an acute (mod-
erate to severe) episode of major depression (according to
the International Classification of Diseases, German
Modification 10, ICD-10-GM codes F32.1, F32.2, F33.1,
F33.2); and 5) no psychiatric comorbidities that could
influence treatment (e.g., addiction, schizophrenia, suici-
dal tendency). A total of 88,437 patients were included in
the analysis. Cost data for rehabilitation were provided
Figure 1 State-transition diagram (simplified version)
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by the German Pension Insurance Office for the year
2009.19 As the claims data provided information on inter-
ventions in the different cost categories, they were used to
calculate the average resource use and costs per patient in
the respective cost category.
In addition, the German clinical practice guideline on
depression20 was used to identify and calculate treatment-
related and health state–specific resource use for outpati-
ent care, psychotherapy, and drugs. It was not used for
estimating inpatient-related resource use, as hospital costs
were based on a daily charge (also including drug costs).
The market proportions of the prescriptions for the vari-
ous antidepressants were obtained from the German
Pharmaceutical Prescriptions Report.21 Estimations for
remaining issues, such as the proportion of patients
receiving first- or second-line treatment, were obtained
from an expert survey (13 GPs and specialists in outpati-
ent and inpatient care). Details of the SHI claims data
and the patient sample, as well as of the selection of
experts, the structure of the questionnaire, and the survey
results, are described elsewhere.16
The following German pricing sources were used: The
Uniform Value Scale22 with the point value of 201123 for
outpatient and psychotherapy services, the Pharmacy
Price Schedule (Lauer Taxe)24 for drug costs, as well as
the National Accounts 2010 of the Federal Statistical
Office25 for productivity loss. The index year for costs
was 2011. If prices were not available for 2011, they were
adapted to 2011 by means of the Consumer Price
Index.26 See Table 1 for an overview of the data sources
used to estimate and valuate resource use per cost cate-
gory and health state.
Determination of Resource Use and Costs per
Category
A bottom-up approach was used to determine the costs
for outpatient care, psychotherapy, drugs, inpatient care,
and co-payments. Cost data on productivity losses and
rehabilitation were only available in an aggregated form,
requiring a top-down calculation.18
For outpatient care, psychotherapy, and drugs, the
costs are the product of the amount of resources used
per patient and the corresponding unit costs.22 In cases
where SHI claims data showed that only a proportion of
patients received interventions in these three categories,
the costs were attributed to the specific proportion. For
drugs, the average resource use per patient was measured
in defined daily doses.20 For dose intervals, the dose was
averaged. For different package sizes and administration
regimens, the least costly options were chosen. Rebates
from drug manufacturers and pharmacies to the SHI
were subtracted. In respect of second-line treatment, we
calculated costs for three different treatment options:
switching of drugs, combination of drugs, and augmen-
tation with lithium.20 Adherence to treatment was not
considered in our analysis, as the study population in the
model was matched to the study population from the
benefit assessment, which did not consider this out-
come.14,15 For hospitalization and rehabilitation, the
costs were calculated as the number of days in hospital
multiplied by a per-diem charge, including drug costs.16
For the estimation of productivity losses, the average
number of annual sick days per patient was multiplied
by the average value of a lost working day,16,25 using the
human capital approach. Co-payments were calculated
for the categories outpatient care, drugs, inpatient care,
and rehabilitation using the German co-payment regula-
tions of 2011.27
Health State Costing
The costing approaches and the variables for health state
costing varied depending on how costs were incurred
over the time horizon of the Markov model. Costs
incurred intermittently over the time horizon
Table 1 Data Sources Used in the Stepwise Hybrid Approach to Estimate and Valuate Resource Use per Cost Category, or
Health State
Data Sources
SHI
Claims Data
Guideline
Recommendations
Expert
Survey Statistics Literature
Fee
catalogues
Outpatient care and psychotherapy RC RS
RS
V
Drugs RC RS
Inpatient care RC V
Rehabilitation RC V
Productivity loss RC V
Note: RC = resource use per cost category; RS = resource use per health state; V = valuation.
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(‘‘intermittent costs’’), such as costs for hospitalization,
rehabilitation, and productivity losses, were transformed
top-down to constant costs per period. The only health
state–specific variable was the proportion of patients
incurring these costs. We assumed that patients were
hospitalized and/or in rehabilitation only once per year.
In addition, we assumed that sick days were equally dis-
tributed over a year.
For costs incurred almost continuously throughout
the time horizon of the model (‘‘continuous costs’’), such
as costs for outpatient care and drugs (including related
co-payments), the health state–specific costs were deter-
mined in a bottom-up approach. This means that we
jointly considered different resource uses per cost cate-
gory in each health state and the different proportions of
patients in the cost categories according to the health
state. The variables for resource use in outpatient care
were the following: 1) proportion of patients visiting a
GP or specialist; 2) number of visits to a physician
(either a GP or specialist); 3) type of laboratory or
physician service used; and 4) the proportion of patients
receiving outpatient care. The variables for drug costs
were the following: 1) treatment options (continuation of
first-line treatment, switching of drugs, combination of
drugs, or augmentation with lithium) and 2) proportions
of patients receiving the respective treatment options.
For psychotherapy, a mixed approach was used: ana-
logous to the calculation of the costs for inpatient care
and rehabilitation, an average costs per 8 week Markov
cycle was multiplied with the proportions of patients
receiving psychotherapy in the different health states,
but we assumed higher costs at the beginning of therapy
(e.g., for medical history taking). This information was
based on the patient-specific SHI claims data. Transition
costs were calculated once when entering second-line
treatment health states, as we assumed higher treatment
costs for these health states in the first few weeks than in
the following weeks (one-off costs). Figure 2 summarizes
the approaches used for the calculation of costs per cate-
gory and per health state.
Figure 2 Calculation steps taken to estimate the input costs per cost category and health state
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Results
Results per Cost Category
A detailed listing of resource use (based on the relevant
items of the German Uniform Value Scale),22 as well as
cost ranges per 8-week period for outpatient care and
psychotherapy, are provided in Online Appendix 1. The
average daily dose for all drugs considered and the costs
per day and per 8-week period are provided in Online
Appendix 2. To determine the resource use for psy-
chotherapy, we assumed that, according to the SHI
claims data, 25% of the patients with psychotherapy had
received behavioral therapy, 50% in-depth psychological
therapy, and 25% other forms of therapy. In addition,
50% of the patients incurred additional costs for psycho-
logical testing and consultations and 25% incurred addi-
tional costs for the detailed documentation of medical
history, which we defined as one-off costs per average
patient in this model. A total of 6.5% of patients were
hospitalized for about 56 days on average per year, at an
average daily fee of e174.16 A total of 2.1% underwent
rehabilitation in 2009 with an average length of 40 days;
the average daily cost was e101.19 An average of 14% of
patients were on sick leave in the year 2010.16 The aver-
age number of sick days per patient on sick leave was 88
for the year 2010, with an average lost working day cost-
ing e96.16,25 The total costs incurred per 8-week period
are shown in Table 2.
Variables for Health State Costing
Differences in costs for all health states resulted from dif-
ferent proportions of patients incurring costs. For outpa-
tient care, drugs, and related co-payments, the
proportion of patients incurring costs in these categories
varied from 98% for different health states to 100%
(health state ‘‘FT remission’’). In all of the other cost
categories (inpatient care, psychotherapy, rehabilitation,
and productivity loss), no patients incurred costs in the
health state of ‘‘FT remission.’’ With regard to all other
health states up to 35% of patients underwent psy-
chotherapy in addition to drug therapy, up to 2% were
hospitalized, up to 0.4% were in rehabilitation, and up to
2.3% were on sick leave, per eight-week period. For
detailed results see Online Appendix 3. Health state–specific
variables determining resource use in the categories ‘‘outpa-
tient care’’ and ‘‘drugs’’ are shown in Table 3.
Results per Health State and Cost Category
The average input costs per patient per 8-week period
varied, depending on the drug strategy and health state.
However, differences in cost parameters depending on
the drug strategy mainly arose from the different drug
costs themselves (Table 4). In first-line treatment,
changes in costs per health state were therefore caused
only by the respective proportion of patients incurring
costs in the different cost categories. Cost differences in
second-line treatment were mainly caused by drug com-
binations and treatment switching. Cost-intensive drug
strategies in first-line treatment therefore became less
costly in second-line treatment, whereas low-cost strate-
gies in first-line treatment became more costly in second-
line treatment.
In outpatient care, few drug strategy–specific differ-
ences in costs could be reliably determined for the various
cost categories for the 1-year time horizon. Differences
were shown for monitoring costs, which were higher for
TCAs, due to the costs for electrocardiograms, and lower
for placebo. No drug strategy specific costs could be veri-
fied for the other cost categories. Onetime costs for enter-
ing different health states lay between e33 and e76. There
were no onetime costs for the transition into the health
states ‘‘FT acute,’’‘‘remission,’’ and ‘‘response.’’ From the
SHI insuree perspective, hospitalizations caused the high-
est costs of all cost categories (except for the health states
‘‘FT remission,’’‘‘FT response,’’ and ‘‘ST response/remis-
sion after FT disc.’’), namely, up to 51% of the total costs
Table 2 Constant Components of Intermittent Costs per 8-Week Period
Cost Category
Psychotherapy Inpatient Care Rehabilitation Productivity Loss
Lump sum per 8-week perioda e243 (+ e53)b e9,730 e4,021 e1,407
Note: For patients concerned with these cost sectors.
a. Sources (all German): SHI claims data, point value 201123; Statistics of the German Pension Insurance 200919; National Accounts 2010 of the
Federal Statistical Office25; Uniform Value Scale 2011.22
b. One-off costs, see Online Appendix 1.
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(Table 5 and Figure 3). Drug costs were ranked second
with up to 36% (except for the health state ‘‘FT remis-
sion,’’ where these costs were 71%, as no costs for inpati-
ent care, rehabilitation, and psychotherapy are incurred
here) followed by outpatient care (up to 30%) and psy-
chotherapy costs (up to 22%). From the societal perspec-
tive, loss of productivity accounted for the largest share
of the total costs (up to 41%).
From the SHI insuree perspective, the average total
input costs per patient per 8-week period varied from
e55 for SSRIs (respectively e32 for placebo) in the health
state ‘‘FT remission’’ to e506 for agomelatine in ‘‘FT
relapse.’’ From the societal perspective, the lowest costs
were equal to those of the SHI insuree perspective, as
zero costs for productivity loss and rehabilitation were
assumed for patients in ‘‘FT remission.’’ The highest
costs from the societal perspective were e724 for agome-
latine in ‘‘FT relapse.’’ The total input costs per strategy
for each health state are represented in Online
Appendixes 4 and 5.
Table 3 Variables for Resource Use per Health State (Continuous Costs)
Markov Health State Outpatient Care (Services per Patient)a
Type of Druga,b (Treatment
Option per Patient)
‘‘FT acute’’ 6 visits to a physicianc FT drug
2 blood tests
1 electrocardiogram (only for patients
receiving TCAs)
‘‘FT response’’ 2 visits to a physicianc FT drug
1 electrocardiogram (only for patients
receiving TCAs)
‘‘FT remission’’ 1 visit to a physicianc FT drug
‘‘FT relapse’’ 3 visits to a physiciand FT drug
‘‘ST after disc. due to AEs’’
and ‘‘ST response/remission
after FT disc.’’
3 visits to a physiciand + 3 additional
visits when entering the absorbing state
Treatment switching for 100% of patients:
ST drug
‘‘ST no response’’ and ‘‘ST
relapse’’
3 visits to a physiciand + 3 additional
visits when entering the absorbing state
Treatment switching for 60% of patients:
ST drug
Administration of lithium once for 10% of
patients
Augmentation with lithium for 10% of
patients: FT drug and lithium
Control of blood levels once for 50% of
patients
Combination of FT drug and ST drug for
30% of patients
Note: FT = first-line treatment; ST = second-line treatment; TCAs = tricyclic antidepressants.
a. Per 8-week period.
b. See Online Appendix 2 for daily drug dose.
c. Assumption based on expert survey: 75% of the patients were treated by a GP and 25% by a specialist.16
d. Assumption based on expert survey: 25% of the patients were treated by a GP and 75% by a specialist.16
Table 4 Average per Patient Input Costs for the Markov Model: Drug Costs (Including Co-Payments for Drugs)
Drug Costs per 8-Week Period (in e) Depression FT Depression ST
Mirtazapine (study drug) 28 39–44
Venlafaxine (study drug) 55–56 25–33
Bupropion (study drug) 104–106 37–50
Duloxetine (study drug) 148–150 25–46
SSRIs (comparator; main agent paroxetine)a 22–23 54–58
TCAs (comparator; main agent maprotiline)a 23 39–44
Trazodone (comparator) 67–69 37–45
Agomelatine (comparator) 160–164 36–58
Note: FT = first-line treatment; SSRIs = selective serotonin reuptake inhibitors; ST = second-line treatment; TCAs = tricyclic
antidepressants.
a. For SSRIs and TCAs, in each case the least expensive drug was defined as the main agent from the drug class.
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Discussion
We presented a hybrid approach for estimating costs as
input data for a Markov model in depression, using
claims data from the German SHI system. Health state–
specific variables were determined by means of expert
surveys and guideline recommendations. Depending on
the type of data and the time-related aspects of costs
(continuous vs. intermittent costs), we combined two dif-
ferent approaches (bottom-up and top-down) for assign-
ing costs at the level of each drug strategy and health
state. The lowest costs (excluding placebo) were incurred
under SSRIs in the health state ‘‘FT remission’’ and the
highest costs under agomelatine in ‘‘FT relapse’’ from
both perspectives. While input costs differed considerably
across health states, they only showed minor differences
across drug strategies. From the SHI insuree perspective,
the most relevant cost factor was hospitalization. From
the societal perspective, it was productivity loss.
Although the objective of our study was to derive
input cost parameters for a Markov model, our estimates
could feed into any multistate model in major depression
using assumptions and health states similar to those we
used. Nevertheless, our estimates cannot be meaningfully
used for models attributing costs to health care interven-
tions, nor in international contexts, without the neces-
sary adjustments. More generally, however, our methods
could be used for international contexts supplying claims
data, clinical practice guidelines, and expert surveys, as
well as for other illnesses whose complexity requires the
attribution of costs to health states instead of health care
interventions.
Table 5 Costs in Individual Cost Categories as a Proportion of Total Costs (Rangesa Depending on Health States).
Cost Category SHI Insuree Perspective Societal Perspective
Outpatient costs 19.9% [14.6% to 30.4%] 13.2% [9.3% to 22.9%]
Psychotherapy 16.7% [0% to 21.7%] 10.3% [0% to 13.8%]
Drugs 25.3% [9.6% to 70.7%b] 18.8% [6.1% to 70.7%b]
Inpatient costs 34.4% [0% to 50.9%] 21.5% [0% to 32.4%]
Co-payments 3.7% [2.8% to 6.4%] 2.6% [1.8% to 6.4%]
Indirect costs 30.9% [0% to 40.5%]
Rehabilitation 2.7% [0% to 5.2%]
a. Ranges may vary considerably depending on the importance of certain cost categories across health states.
b. This percentage occurs in the health states ‘‘FT remission’’ and ‘‘FT response’’ where are no or very low costs in the other cost sectors.
Figure 3 Average per patient input costs in e for the Markov model per cost category per 8-week period (societal perspective)
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Even though treatment pathways differ between coun-
tries, it would be useful to conduct health economic eva-
luations with more detailed approaches for health state
costing. The complete and reproducible presentation of
cost data would not only be a valuable basis for financial
decisions, it could generally accelerate the conduct of
future evaluations and increase the comparability of
results.
Comparison With Previous Research
Our study extends previous research not only by present-
ing a stepwise hierarchical approach using different data
sources for costing but also by presenting important
health-specific variables and results in a transparent man-
ner. In contrast, in previous models, the estimation of
resource use was largely based on expert surveys.3 From
seven health economic evaluations4–6,10–13 investigating
similar study populations, interventions, and health
states, or choosing a comparable time horizon or cost
categories, only one evaluation13 described the data
sources and health state–specific variables and results.
Some named data sources and summarized final input
costs6,10 or addressed certain health state–specific vari-
ables,12 but did not describe how costs were attributed to
different health states. Another described data sources
and provided some information on costing, without
describing how costing was performed with respect to
health states.11 A further evaluation did not mention
health state–specific costing at all, even though a Markov
model was chosen.4 None reported the costing approach
(bottom-up vs. top-down) used or explained the choice
of data sources.
As we identified no other German health economic
evaluation reporting health state–specific input costs, no
context-specific comparison with previous research in
Germany was possible. However, we were able to com-
pare single cost parameters with results from German
cost studies.12,28–31 Minor deviations in psychotherapy
and inpatient costs could be explained by differences in
the study population, for example, with regard to age,30
definition of therapeutic indication, or cost classifica-
tion.28,29 We calculated costs of e9,730 per hospitaliza-
tion period; higher costs of e11,81312 and e10,67931 have
been reported in the literature. This is because daily costs
were lower in our calculation, as we also considered day-
time clinics, which charge lower daily fees than inpatient
clinics. The average length of stay varied between 49 and
63 days,12,31 compared with 56 days in our calculation.
As no other study calculated costs for outpatient care
and drugs in a bottom-up approach for each health state,
we could not compare our findings in these cost sectors
with other studies. However, the cost structure was com-
parable to structures reported previously,12,29–31 with
inpatient costs representing the greatest cost factor from
the SHI insuree perspective. In addition, we compared the
annual total costs predicted in the model with the pub-
lished annual total costs reported in German cost studies
and health economic evaluations.12,29,30 Deviations from
the results of our analysis could be explained by differ-
ences in patient characteristics (e.g., age) in three stud-
ies.28–30 However, our results also deviated from those of
an analysis with similar patient characteristics. This
might be explained by different assumptions on the
number of outpatient visits and the proportion of hos-
pitalized patients.12
Limitations
In our costing approach, we used three different types of
data sources to measure resource use: claims data, clinical
practice guidelines, and expert surveys. All of these sources
have advantages and limitations. Claims data reflect the
‘‘as-is’’ situation and allow the determination of the entire
resource use, as well as the real net prices. In addition,
they more or less precisely describe treatment periods.
Disadvantages include potential biases due to variations in
1) patient groups, 2) regional characteristics, 3) prescribing
practices of physicians (e.g., noncompliance with guideline
recommendations), and 4) reimbursement contracts
between SHI funds and service providers. Assumptions
based on guideline recommendations are not affected by
these potential problems to the same extent. However,
guidelines reflect a normative situation, not necessarily the
actual resource use. Assumptions based on expert surveys
offer the advantage of obtaining very detailed and specific
information not always available from other sources.
Expert surveys are, however, considered to be the informa-
tion source with the lowest internal validity9 and should
therefore be used only in cases where data cannot be
obtained from other sources or to supplement data from
more valid sources. In addition, the selection and number
of experts cannot be considered representative and there-
fore might have produced biased assumptions.
In addition, further limitations may apply:
1. Due to the requirements of the Markov model we
could not use a bottom-up approach for cost estima-
tion in all cost categories. For intermittent costs, the
distribution of the average yearly costs to 8-week
periods and health states is imprecise compared with
bottom-up health state costing of continuous costs.
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2. We used a micro-costing approach only for the esti-
mation of drug costs. In the outpatient sector, reim-
bursement in Germany is based on so-called
‘‘complex fees’’ (payment of a lump sum for differ-
ent components of treatment) according to the
German Uniform Value Scale. Reimbursement of
the inpatient sector is based on daily rates. A
macro-costing approach is therefore a reasonable
approach to represent real costs for the SHI in these
sectors.18 However, from the societal perspective,
the SHI administrative costs do not necessarily rep-
resent the true costs to society, especially due to the
increasing proportion of complex fees.
3. We assumed that patients were hospitalized only
once per year. In the case of severe depression it is
possible that patients are hospitalized several times a
year. According to the SHI claims data, patients
were hospitalized for about 56 days on average per
year. The calculation for inpatient care is made on
the basis of average daily rates. Therefore, the inpa-
tient costs are independent of the number of hospi-
talizations per year, as long as the total number of
inpatient days per year remains the same. However,
according to our sensitivity analyses, the costs for
outpatient care, drugs, and psychotherapy could
slightly increase. The reason for this is that, with
higher hospitalization rates, the average length of
stay is reduced, and it therefore becomes possible
that patients induce costs in both outpatient and
inpatient care during one cycle. This is in contrast to
our assumption, where patients can be in either
inpatient or outpatient care in the same cycle (since
56 days correlate with the length of one Markov
cycle).
We identified only minor cost differences in the monitor-
ing of patients taking antidepressants, which is consistent
with the information provided in the German guideline
on depression.20 We took these differences into account.
Cost differences between drug strategies arose mainly
from the different drug costs themselves.
All limitations can cause uncertainties that may not
be fully examined and adjusted for in deterministic and
probabilistic sensitivity analyses.
Conclusion
Our findings indicate that, in order to estimate costs in
health economic evaluations of treatments for mental ill-
nesses such as depression, it can be necessary to link dif-
ferent data sources and costing approaches using a
systematic hybrid approach to meet the requirements of
the decision-analytic model. This would enable the
determination of health state–specific costs, even if
interventions are not directly related to health states in
depression. As the systematic hybrid approach can
increase complexity, the corresponding calculations
should be presented transparently. Our findings could
provide useful input for future models.
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